Medicaid expansion was associated with earlier diagnosis, more timely initiation of guideline-concordant care, and better ...

Study compared telehealth with in-person meeting as a modality for effective delivery of early palliative care.

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...

On September 3, OBX-115, a novel TIL therapy, was granted FDA regenerative medicine advanced therapy (RMAT) designation in ...

AbbVie ABBV announced that it has submitted a biologics license application (BLA) to the FDA seeking accelerated approval for ...

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid ...

Survival in NSCLC improved with guideline-concordant care in lung cancer, and several factors can be addressed to reach more ...

The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment ...

Tagrisso has been approved for some adults with locally advanced, unresectable stage 3 non-small cell lung cancer.

The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.

Panelists discuss how HER2-directed therapies in non–small cell lung cancer (NSCLC) are evolving, with experts examining the distinction between HER2 mutation and expression, evaluating the efficacy ...

Patients with stage I NSCLC who receive stereotactic body radiotherapy rarely experience acute toxicities or 90-day mortality ...